Crossword Puzzle

1234567891011121314151617
Across
  1. 4. VANISH: 67% of patients on BREXAFEMME at day 25
  2. 5. VANISH: Occurred on Day 11
  3. 8. CANDLE: Test completed to confirm VVC recurrence
  4. 11. Oral Prescription azole for VVC
  5. 12. OTC azole supplied as vaginal suppository
  6. 15. Oral azole approved for RVVC only
  7. 17. BREXAFEMME is contraindicated during this
Down
  1. 1. Number of BREXAFEMME tablets in daily dose
  2. 2. Increasing rates observed with widespread use of fluconazole
  3. 3. VANISH:BREXAFEMME demonstrated complete _ at day 10
  4. 6. 3+ infections in a year
  5. 7. VANISH: Based on patient-recorded symptom diaries
  6. 9. Azole MOA blocks this
  7. 10. May be associated with itching, burning, and messiness
  8. 13. Most common non-albicans Candida
  9. 14. CANDLE: Occurred on week 24
  10. 16. Blocked by BREXAFEMME